Since the last update in June 2022, Health Canada has approved three more biosimilars (Myxredlin, Rymti, Elonox) in 2022 [1].
Canada approves three more biosimilars in 2022
Biosimilars/News
|
Posted 28/05/2024
0
Post your comment
![Health Canada V13I20 Health Canada V13I20](/var/gabi/storage/images/media/images/health-canada-v13i20/19497-2-eng-GB/Health-Canada-V13I20_large.jpg)
The biosimilars approved in the second half of 2022 are:
– Baxter’s Myxredlin, biosimilar of Novo Nordisk’s NOVOLIN (human insulin, recombinant) – authorized on 3 August 2022
– Lupin Pharma’s RYMTI, biosimilar of Immunex’s Enbrel (etanercept) – authorized on 13 September 2022 [2]
– Fresenius Kabi’s Elonox and Elonox HP, biosimilars of Sanofi’s Lovenox and Lovenox HP (enoxaparin sodium) – authorized on 26 October 2022
Myxredlin (insulin human in 0.9% sodium chloride injection) is available in a standardized concentration of 100 units/100 mL in a flexible plastic container indicated to improve glycaemic control in adults and paediatric patients with diabetes mellitus.
Lupin’s Rymti (etanercept) is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis, and is available as an injectable easy-to-use pre-filled pen and a pre-filled syringe [2].
Elonox (enoxaparin sodium) is the second biosimilar product introduced in Canada by Fresenius Kabi. Elonox and Elonox HP are indicated for deep vein thrombosis and comes in seven pre-filled syringe dosages. All are now available and listed on every provincial formulary across Canada.
The Health Canada authorization of Elonox, was based on the evidence submitted to Health Canada including analytical, and clinical data in healthy volunteers and patients. Indications have been granted on the basis of similarity between the biosimilar and the reference biological drug.
By end of March 2024, Health Canada had approved 59 biosimilars within the product classes of human growth hormone, granulocyte colony-stimulating factor (G-CSF), insulin, monoclonal antibodies and tumour necrosis factor (TNF)-inhibitor, for use in Canada [3].
Related article
First denosumab biosimilars approved in Canada and the US
LATIN AMERICAN FORUM View the latest headline article: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO Ver el último artículo de cabecera: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. |
References
1. GaBI Online - Generics and Biosimilars Initiative. Canada approves five biosimilars in last seven months [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/news/canada-approves-five-biosimilars-in-last-seven-months
2. GaBI Online - Generics and Biosimilars Initiative. Canada approves etanercept biosimilar Rymti [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/news/canada-approves-etanercept-biosimilar-rymti
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-canada
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.
Research
Budget impact analysis of Rixathon introduction in Chile for non-Hodgkin lymphoma
Biosimilars in inflammatory bowel disease: are we ready for multiple switches
General
Humira's resilience in the face of biosimilar competition
Boehringer Ingelheim to expand access to adalimumab biosimilar
Richmond to launch similar biologicals bevacizumab Yriviak and adalimumab Armixa
![01 AA007239 01 AA007239](/var/gabi/storage/images/media/images/01-aa007239/21704-1-eng-GB/01-AA007239_large.jpg)
Biosimilars/News Posted 06/08/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets
![picture09 picture09](/var/gabi/storage/images/media/images/picture09/2207-2-eng-GB/picture09_large.jpg)
Post your comment